1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Guerbet SA

Guerbet SA

5.90
EUR
+0.09
(+1.55%)
336.51MMarket Cap
Mar 24Next Earn
Guerbet SA
GETTEX:4G8
(Gettex)

Recent

price

5.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
28.94
31.05
33.14
32.01
33.54
40.09
62.4
64.56
63.18
65.06
56.88
58.33
60.99
62.94
67.53
63.31
- -
Revenue per Share
0.48
1.18
1.67
1.68
2.14
3.21
2.33
3.69
3.72
2.97
1.45
2.59
-3.26
1.89
1.28
-8.59
- -
Basic EPS, GAAP
-0.28
0.1
0.84
1.85
2.36
2.4
-0.89
0.76
2.62
0.28
4.82
5.31
-1.59
-2.1
1.92
3.53
- -
Free Cash Flow per Basic Share
0.56
0.45
0.45
0.5
0.5
0.5
0.64
0.86
0.85
0.85
0.7
0.7
0.85
0.5
0.5
- -
- -
Dividend per Share
17.26
17.61
18.54
19.56
21.26
22.92
25.22
27.28
29.28
30.93
29.21
32.08
30.08
30.08
31.28
21.16
31.28
Book Value per Share
14.45
14.67
15.57
16.59
17.69
15.46
16.72
18.62
14.72
15.85
14.26
17.14
22.32
22.36
22.82
16.29
22.82
Tangible Book Value per Share
12
12
12
12
12
12
12
13
13
13
13
13
13
13
13
13
13
Basic Weighted Avg Shares
353
379
404
391
409
490
776
809
795
819
717
736
769
796
851
799
- -
Sales/Revenue/Turnover
2.35
5.95
8.29
7.69
9.57
12.25
7.21
10.02
8.32
6.32
5.97
5.36
5.58
4.92
5.73
1.01
- -
Operating Margin (%)
20
20
22
24
25
29
49
43
42
59
58
58
123
58
73
162
- -
Depreciation Expense
6
14
20
20
26
39
29
46
47
37
18
33
-41
24
16
-108
- -
Net Income, GAAP
- -
19.71
26.43
26.06
27.93
35.6
38.53
30.82
29.53
27.1
18.02
- -
- -
28.03
30.39
- -
- -
Effective Tax Rate (%)
1.67
3.81
5.05
5.25
6.38
8.01
3.73
5.72
5.89
4.56
2.55
4.43
-5.34
3
1.89
-13.56
- -
Profit Margin (%)
102
84
88
88
90
243
296
295
157
299
268
259
270
352
335
359
335
Working Capital
- -
80
67
62
45
301
331
287
193
341
318
300
278
374
351
392
351
LT Debt
211
215
226
238
259
282
315
342
367
389
368
405
380
378
392
260
392
Total Equity
- -
6.64
6.99
6.45
8.04
7.56
4.82
7.44
6.42
4.79
4.59
- -
- -
3.71
4.31
- -
- -
Return on Invested Capital (%)
- -
6.23
6.72
6.37
8
8.29
4.96
7.19
7.3
5.46
2.99
- -
- -
4.56
4.25
- -
- -
Return on Capital (%)
2.83
6.78
9.25
8.82
10.51
14.49
9.69
14.07
13.21
9.88
4.82
8.45
-10.48
6.3
4.16
-32.77
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
13
27
44
LT Borrowings
361
362
338
LT Finance Leases
14
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
245
443
337

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
582
604
590
Cash, Cash Equivalents & STI
93
96
86
Accounts Receivable, Net
150
172
173
Inventories
305
326
301
Total Current Liabilities
229
240
254
Payables & Accruals
- -
- -
- -
ST Debt
13
27
44
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.14%
-5.31%
-33.58%
Free Cash Flow
128.85%
-38.91%
83.6%
Net Income, GAAP
-114.78%
-222.25%
-773.53%
Sales/Revenue/Turnover
6.29%
2.29%
-6.16%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
796
2024
- -
- -
851
2025
- -
- -
799

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.89
2024
- -
- -
1.28
2025
- -
- -
-8.59

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.5
2024
- -
- -
0.5
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Guerbet S.A. Guerbet SA develops, manufactures and markets contrast agents, delivery systems, medical devices and related solutions for diagnostic and interventional medical imaging, including X-ray imaging products such as Xenetix, Optiray, Oxilan and Telebrix; MRI products such as Dotarem; and other contrast products for echography, nuclear medicine and fine chemicals, along with brands including Lipiodol, Endorem, Artirem and Lumirem. The company operates production sites in France, the United States, Ireland and Brazil, with Europe accounting for 37% of net sales; it targets healthcare providers in diagnostic imaging (MRI and CT) and interventional radiology segments worldwide. Founded in 1926 and headquartered at 15 rue des Vanesses, Zone Paris Nord II, Villepinte, France, Guerbet recently formed a strategic partnership with Nuclidium on May 22, 2024, to develop targeted copper-based radiopharmaceuticals, sold assets including the SeQure and DraKon microcatheters to Argon Medical in January 2025 to expand its oncology portfolio, reported revenue of €851 million in 2024 with return to growth in Q3 2025, and announced a change in general management while confirming full-year financial targets.